6(top 2%)
Impact Factor
6.7(top 2%)
extended IF
184(top 1%)
citing journals
citing authors

Most Cited Articles of Clinical Pharmacokinetics in 2005

Quantification of lean bodyweight2005569
Pharmacokinetics and pharmacodynamics of systemically administered glucocorticoids2005502
Pregnancy-induced changes in pharmacokinetics: a mechanistic-based approach2005478
Clinical pharmacokinetics of imatinib2005426
Mechanism-based inhibition of cytochrome P450 3A4 by therapeutic drugs2005342
Ezetimibe: a review of its metabolism, pharmacokinetics and drug interactions2005281
Clinical pharmacokinetics of cyclophosphamide2005251
Antimicrobial therapy in critically ill patients: a review of pathophysiological conditions responsible for altered disposition and pharmacokinetic variability2005221
The influence of age and sex on the clearance of cytochrome P450 3A substrates2005212
Comparative pharmacokinetics of vitamin K antagonists: warfarin, phenprocoumon and acenocoumarol2005205
Buprenorphine: clinical pharmacokinetics in the treatment of opioid dependence2005200
Pharmacokinetics/pharmacodynamics of bisphosphonates: use for optimisation of intermittent therapy for osteoporosis2005169
Pharmacokinetic/pharmacodynamic relationships of asparaginase formulations: the past, the present and recommendations for the future2005162
Oral bioavailability of posaconazole in fasted healthy subjects: comparison between three regimens and basis for clinical dosage recommendations2005160
Clinical pharmacokinetics of atomoxetine2005159
Effect of genetic polymorphisms in cytochrome p450 (CYP) 2C9 and CYP2C8 on the pharmacokinetics of oral antidiabetic drugs: clinical relevance2005149
Pharmacokinetics of hydroxyethyl starch2005147
Clinical pharmacokinetics of losartan2005131
Clinical pharmacokinetics and summary of efficacy and tolerability of atazanavir2005119
The hepatic sinusoid in aging and cirrhosis: effects on hepatic substrate disposition and drug clearance2005116
Single-dose clinical pharmacokinetic studies of gefitinib2005110
Pharmacokinetic drug interactions of gefitinib with rifampicin, itraconazole and metoprolol2005106
Pharmacokinetic/pharmacodynamic modelling of antibacterials in vitro and in vivo using bacterial growth and kill kinetics: the minimum inhibitory concentration versus stationary concentration2005104
Pharmacokinetic and pharmacodynamic considerations in the development of therapeutic proteins2005102
Pharmacokinetic profile of ganciclovir after its oral administration and from its prodrug, valganciclovir, in solid organ transplant recipients200596